Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E17.31 EPS (ttm)17.13 Insider Own0.10% Shs Outstand225.91M Perf Week0.45%
Market Cap66.97B Forward P/E14.26 EPS next Y20.80 Insider Trans-13.17% Shs Float218.16M Perf Month-5.75%
Income3.82B PEG2.05 EPS next Q4.97 Inst Own88.30% Short Float1.12% Perf Quarter2.57%
Sales11.24B P/S5.96 EPS this Y24.00% Inst Trans0.05% Short Ratio1.58 Perf Half Y5.47%
Book/sh52.05 P/B5.70 EPS next Y3.70% ROA18.50% Target Price340.33 Perf Year2.01%
Cash/sh16.81 P/C17.64 EPS next 5Y8.46% ROE36.60% 52W Range223.02 - 333.65 Perf YTD-3.23%
Dividend- P/FCF20.83 EPS past 5Y31.30% ROI23.50% 52W High-11.15% Beta0.71
Dividend %- Quick Ratio2.60 Sales past 5Y17.90% Gross Margin88.20% 52W Low32.93% ATR6.81
Employees7350 Current Ratio3.00 Sales Q/Q11.70% Oper. Margin47.90% RSI (14)47.20 Volatility2.42% 2.15%
OptionableYes Debt/Eq0.57 EPS Q/Q21.60% Profit Margin34.00% Rel Volume1.71 Prev Close286.00
ShortableYes LT Debt/Eq0.57 EarningsOct 26 BMO Payout0.00% Avg Volume1.55M Price296.46
Recom2.10 SMA20-1.22% SMA50-2.91% SMA2007.26% Volume2,647,160 Change3.66%
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Oct-27-16 12:24AM  [$$] Overheard: Cheering On a Rival at The Wall Street Journal
Oct-26-16 07:11PM  Edited Transcript of BIIB earnings conference call or presentation 26-Oct-16 12:30pm GMT
06:47PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
05:02PM  Novartis' Is Challenging Biogen on Biogen's Own Turf at Motley Fool
04:10PM  Biogen Q3 Tops; Alzheimer's Data Vs. Eli Lilly Positive
04:07PM  BIIB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016 GlobeNewswire
02:38PM  Biogen is Still in Limbo at Bloomberg
02:31PM  INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
02:07PM  Biogen: Solid Enough to Keep Focus on Alzheimer's, M&A at
01:07PM  Biogen Posts 3Q Net of $1B on $3B Revenue (BIIB) at Investopedia
01:06PM  Eaton Vance Worldwide Health Sciences Fund 3rd Quarter Commentary
11:55AM  Biogen: Heads Is a Win, Tails Is Complicated at The Wall Street Journal
11:54AM  Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta
10:47AM  Biogen profit tops expectations; focus on CEO search, new drugs
10:05AM  Biogen Rises on Solid Earnings Beat
08:54AM  Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales
08:50AM  US STOCKS-Wall St set to open lower as Apple drags
08:40AM  Biogen (BIIB) Beats on Q3 Earnings and Sales
08:19AM  Morning Movers: Biogen, Boeing, Coca-Cola Gain on Earnings; General Motors Slips at
08:03AM  Biogen (BIIB) Stock Rises, Q3 Results Beat Expectations
08:00AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Biogen Inc. To Contact The Firm Before Lead Plaintiff Deadline GlobeNewswire
07:55AM  [$$] Biogen Profit Easily Tops Views at The Wall Street Journal
07:21AM  Biogen stock lifts as much as 3% as MS drugs propel third-quarter beat at MarketWatch
07:15AM  Short Sellers Cant Make Up Their Minds on Major Biotechs at 24/7 Wall St.
07:10AM  Biogen tops Street 3Q forecasts
07:10AM  BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:07AM  Q3 2016 Biogen Inc Earnings Release - Before Market Open
07:06AM  Drugmaker Biogen quarterly profit rises 7 pct
06:59AM  Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion Business Wire
Oct-25-16 04:00PM  5 Stocks to Watch Before the Market Opens Tomorrow
11:26AM  Here's the big news we're likely to hear when Vertex, Biogen report Q3 this week at
08:27AM  Drug Stock Earnings to Watch on Oct 26: BIIB, MDCO & More
Oct-24-16 06:04PM  Labaton Sucharow LLP Files Class Action Lawsuit on Behalf of Biogen Inc. Investors GlobeNewswire
04:15PM  Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC
02:51PM  What to Look for When Biogen (BIIB) Reports Q3 Results
Oct-23-16 10:35AM  Top Health Care Earnings Coming Next Week at 24/7 Wall St.
Oct-21-16 12:13PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit BIIB GlobeNewswire
Oct-20-16 10:29AM  7 Drug Stocks to Consider as Biosimilars Pick Up Pace
10:21AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?
09:58AM  Biotech Stocks: Do Earnings Even Matter Anymore? at
09:55AM  Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains at 24/7 Wall St.
08:06AM  What Are the Drivers behind the Success of Soliris?
08:05AM  What Biogen Is Doing that Put It in Good Favor with Analysts
Oct-19-16 04:04PM  Biogens Multiple Sclerosis Drug Driving Its Growth This Year
03:04PM  4 Strategic Areas Expected to Boost Biogens Growth in 2016
12:39PM  Biogen Expected to Report Modest Revenue Growth in 3Q16
08:37AM  Better Buy: Biogen Inc. vs. Gilead Sciences, Inc. at Motley Fool
08:05AM  Why Vertex Lowered Its Guidance for Orkambi
Oct-18-16 03:28PM  How Did Markets React to the Feds September 2016 Minutes?
09:21AM  A new drug is slowing memory loss in Alzheimer's patients at CNBC
07:37AM  Alzheimer's Remains a Top Priority for Big Pharma at Motley Fool
Oct-17-16 04:03PM  Celgene Pitted Against Gilead, Biogen In Crohn's Drug Battle
Oct-14-16 11:04AM  How Valeant Is Trying to Improve Its Profit Margins
10:23AM  BioMarin Issues Encouraging Update on Hemophilia A Drug
07:44AM  Is AveXis a Major Threat to Ionis Pharmaceuticals? at Motley Fool
Oct-13-16 06:28PM  Why This Top Columbia Fund Loads Up On Facebook, Other Stock Leaders
05:02PM  Does a Clinton Victory Scare the Biotech Sector? (AMGN, ILMN) at Investopedia
02:25PM  Biogen Stabilizes Near Major Support
Oct-12-16 12:15PM  Trading the biotech sell-off
08:39AM  Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO
07:28AM  3 Biotechs Most Likely to Be Acquired at Motley Fool
07:10AM  Short Sellers Have Mixed Views on Major Biotechs at 24/7 Wall St.
Oct-11-16 03:40PM  Biogen Gets Competition for SMA Therapy (BIIB) at Investopedia
08:21AM  3 Top Biotech Stocks to Buy Right Now at Motley Fool
Oct-10-16 11:29AM  Better Buy: Biogen vs. Celgene at Motley Fool
Oct-08-16 10:00AM  New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy Business Wire
Oct-07-16 03:26PM  The Key Reason Ionis Pharmaceuticals, Inc. Gained Another 24% in September at Motley Fool
12:22PM  6 Healthcare Stocks Investors Can't Miss in Q3 Earnings
11:51AM  Will Biogen Join Gilead in the Disappointment Club? at
Oct-05-16 01:13PM  Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc. at Motley Fool
12:09PM  Biogen: On the Way to $386? at
12:51AM  [$$] Samsung BioLogics IPO Could Value Firm at $8.2 Billion at The Wall Street Journal
Oct-04-16 12:56PM  [$$] Samsung BioLogics IPO Could Value Firm at $8.2 Billion at The Wall Street Journal
11:32AM  Americas 15 Fastest Growing Companies
Oct-03-16 06:40PM  Forcerank Consensus Rankings- Week of 10/3
01:53PM  A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results
12:12PM  Biogen, Inc. Value Analysis (NASDAQ:BIIB) : October 3, 2016
11:03AM  Gilead: Will New HIV Drugs Overshadow Hep C Worries? at
10:06AM  Could PrEP Offset the Decline in Gilead Sciences Truvada after the Generic Launch?
Oct-02-16 10:05AM  Top 6 Biopharma Gainers of the Past Week at 24/7 Wall St.
05:00AM  Big Pharma vs Big Pharma in court battles over biosimilar drugs Reuters
Sep-30-16 06:03PM  Could Growing HIV Franchise Drive Gilead Sciences Valuation?
03:37PM  Two Stocks With Something To Prove: Biogen And Twitter
12:15PM  Stocks Roar Higher; Apple Still Strong; Will Facebook Break Out Again?
08:31AM  Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : September 30, 2016
Sep-29-16 04:26PM  Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure
03:09PM  Anavex Jumps on Biogen Testing Deal (AVXL, BIIB) at Investopedia
Sep-28-16 07:13PM  Biogen Submits NDA for SMA Drug (BIIB, IONS) at Investopedia
04:12PM  Newbie Anavex Rockets On Testing Deal With IBD 50 Stock Biogen
01:18PM  Why Anavex Life Sciences Corp. Rocketed Higher Today at Motley Fool
11:45AM  Instant Analysis: Biogen's Agreement With Anavex Life Sciences at Motley Fool
11:15AM  Anavex Soars on Biogen Agreement
11:01AM  Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis? at Motley Fool
09:39AM  ETFs with exposure to Biogen, Inc. : September 28, 2016
07:00AM  Anavex Compound to be Tested in Biogen Neurological Protection Model GlobeNewswire
Sep-27-16 10:12AM  Ionis/Biogen Complete Nusinersen NDA Submission in U.S.
07:50AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
Sep-26-16 07:30AM  Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy Business Wire
Sep-23-16 07:35PM  [$$] Rodin Therapeutics, a Neurology Drug Firm, Expands Management Team at The Wall Street Journal
11:38AM  Top 5 profitable Biotech stocks : September 23, 2016
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM